质子泵抑制剂预防重症患者应激性溃疡的获益与风险:1972例观察性队列研究
该回顾性队列研究纳入2016年1月至2018年12月入住苏北人民医院ICU的1972例成人重症患者,其中788例在入ICU 48小时内使用PPI预防应激性溃疡(SUP组),1184例未使用(对照组)。倾向性评分匹配(PSM)前,SUP组消化道出血发生率显著低于对照组(1.8% vs. 3.7%),但医院获得性肺炎和30天死亡率显著更高;PSM后每组358例,两组消化道出血和30天死亡率无显著差异,但SUP组医院获得性肺炎发生率仍显著更高(6.7% vs. 3.1%)。Kaplan-Meier分析显示PSM前SUP组30天累积生存率显著更低,PSM后两组无显著差异。结论认为PPI用于SUP未能显著降低消化道出血和死亡率,但增加医院获得性肺炎风险。
要点
- PSM后SUP组与对照组消化道出血发生率无显著差异[2.2%(8/358)vs. 3.4%(12/358),P>0.05]。
- PSM后SUP组医院获得性肺炎发生率仍显著高于对照组[6.7%(24/358)vs. 3.1%(11/358),P<0.05]。
- PSM后两组30天死亡率无显著差异[15.9%(57/358)vs. 13.7%(49/358),P>0.05]。
- PSM前SUP组30天累积生存率显著低于对照组(log-rank检验:χ2=9.224,P=0.002),PSM后无显著差异(χ2=0.773,P=0.379)。
- PSM前SUP组消化道出血发生率显著低于对照组[1.8%(14/788)vs. 3.7%(44/1184),P<0.05],但医院获得性肺炎和30天死亡率显著更高[6.6%(52/788)vs. 3.5%(42/1184),17.9%(141/788)vs. 13.1%(155/1184),均P<0.01]。
适用人群与场景
- 成人重症患者,2016年1月至2018年12月入住苏北人民医院ICU。
- SUP组:入ICU后48小时内使用PPI预防应激性溃疡者;对照组:未使用PPI者。
研究设计与关键结果
- 回顾性队列研究,纳入1972例成人重症患者(SUP组788例,对照组1184例),经1:1倾向性评分匹配后每组358例。
- PSM前,SUP组较对照组患者年龄更大、基础疾病更多、ICU主要诊断中急性冠脉综合征、急性脑血管病、慢性阻塞性肺疾病急性加重和中毒比例更高、病情更重、应激性溃疡危险因素更多。
- PSM前,SUP组消化道出血发生率显著低于对照组[1.8%(14/788)vs. 3.7%(44/1184),P<0.05];医院获得性肺炎和30天死亡率显著高于对照组[6.6%(52/788)vs. 3.5%(42/1184),17.9%(141/788)vs. 13.1%(155/1184),均P<0.01];艰难梭菌感染发生率两组无显著差异[2.9%(23/788)vs. 1.8%(21/1184),P>0.05]。
- PSM后,两组消化道出血发生率和30天死亡率无显著差异[2.2%(8/358)vs. 3.4%(12/358),15.9%(57/358)vs. 13.7%(49/358),均P>0.05];SUP组医院获得性肺炎发生率仍显著高于对照组[6.7%(24/358)vs. 3.1%(11/358),P<0.05]。
- Kaplan-Meier生存曲线分析:PSM前SUP组30天累积生存率显著低于对照组(log-rank检验:χ2=9.224,P=0.002);PSM后两组30天累积生存率无显著差异(log-rank检验:χ2=0.773,P=0.379)。
证据类型、等级与局限
- 证据类型:回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于重症患者,使用PPI预防应激性溃疡未能显著降低消化道出血发生率和死亡率,但增加医院获得性肺炎风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the benefits and risks of stress ulcer prevention (SUP) using proton pump inhibitors (PPI) for critical patients.
METHODS: The clinical data of adult critically ill patients admitted to the intensive care unit (ICU) of Northern Jiangsu People's Hospital from January 2016 to December 2018 were retrospectively analyzed. All patients who were treated with PPI for SUP within the first 48 hours after ICU admission were enrolled in the SUP group. Those who not received PPI were enrolled in the control group. A one-to-one propensity score matching (PSM) was performed to control for potential biases. The gender, age, underlying diseases, main diagnosis of ICU, drug use before ICU admission, sequential organ failure score (SOFA) at ICU admission, risk factors of stress ulcer (SU) and PPI usage were recorded. The end point was the incidence of gastrointestinal bleeding, hospital acquired pneumonia, Clostridium difficile infection and 30-day mortality. Kaplan-Meier survival curves were plotted, and survival analysis was performed using the log-rank test.
RESULTS: 1 972 critical patients (788 in the SUP group and 1 184 in the control group) were enrolled, and each group enrolled 358 patients after PSM. Prior to PSM, compared with the control group, the SUP group had older patients, more underlying diseases, higher proportion of acute coronary syndrome (ACS), acute cerebrovascular disease, acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and poisoning in main diagnosis of ICU, more serious illness, and more risk factors of SU, indicating that ICU physicians were more likely to prescribe SUP for these patients. The incidence of gastrointestinal bleeding in the SUP group was significantly lower than that in the control group [1.8% (14/788) vs. 3.7% (44/1 184), P < 0.05], while the incidence of hospital acquired pneumonia and 30-day mortality were significantly higher than those in the control group [6.6% (52/788) vs. 3.5% (42/1 184), 17.9% (141/788) vs. 13.1% (155/1 184), both P < 0.01]. There was no significant difference in the incidence of Clostridium difficile infection between the SUP group and the control group [2.9% (23/788) vs. 1.8% (21/1 184), P > 0.05]. After the propensity scores for age, underlying diseases, severity of illness and SU risk factors were matched, there was no significant difference in the incidence of gastrointestinal bleeding or 30-day mortality between the SUP group and the control group [2.2% (8/358) vs. 3.4% (12/358), 15.9% (57/358) vs. 13.7% (49/358), both P > 0.05], but the incidence of hospital acquired pneumonia in the SUP group was still significantly higher than that in the control group [6.7% (24/358) vs. 3.1% (11/358), P < 0.05]. Kaplan-Meier survival curve analysis showed that the 30-day cumulative survival rate of the SUP group was significantly lower than that of the control group before the PSM (log-rank test: χ2 = 9.224, P = 0.002). There was no significant difference in the 30-day cumulative survival rate between the two groups after PSM (log-rank test: χ2 = 0.773, P = 0.379).
CONCLUSIONS: For critical patients, the use of PPI for SUP could not significantly reduce the incidence of gastrointestinal bleeding and mortality, but increase the risk of hospital acquired pneumonia.
参考来源
- Sun J, Wang B, Cao P, et al. [Benefits and risks of stress ulcer prevention with proton pump inhibitors for critical patients: an observational cohort study with 1 972 patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31198136. doi:10.3760/cma.j.issn.2095-4352.2019.05.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。